# A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

> **NCT05452070** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 171 (actual)

## Conditions studied

- Mid Face Volume Deficit

## Interventions

- **DEVICE:** HArmonyCa Lidocaine Injectable Gel

## Key facts

- **NCT ID:** NCT05452070
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-02
- **Primary completion:** 2025-05-08
- **Final completion:** 2025-05-08
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05452070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05452070, "A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05452070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*